PERSPECTA

News from every angle

← Back to headlines

Canaccord Genuity Maintains Buy Rating on ACADIA Pharmaceuticals

Canaccord Genuity has reiterated its 'Buy' rating for ACADIA Pharmaceuticals (ACAD), signaling continued confidence in the company's stock.

6 Aug, 11:47 — 6 Aug, 11:47
PostShare

Sources

Showing 1 of 1 sources
globe-and-mailHigh1d ago

Canaccord Genuity Remains a Buy on ACADIA Pharmaceuticals (ACAD) - The Globe and Mail

Canaccord Genuity Remains a Buy on ACADIA Pharmaceuticals (ACAD)  The Globe and Mail

Read full article →

Related Stories

Grand Hyatt Offers Limited-Time Buffet with Asian Delicacies

11m ago

Central Bank Communication Strategies Discussed

11m ago

Quercus Warns of Underestimated Environmental Impact of Sudoeste Wind Farm

11m ago

Bulgaria Advances Towards Euro Adoption with End of Dual Pricing System

17m ago